Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection
Brand names: Recarbrio
Category: Anti-Infective
FDA status: To Be Discontinued · Last FDA update: Sep 9, 2026 · First posted: Sep 9, 2026 · 1 manufacturers, 1 listed presentations
As of Sep 9, 2026, the FDA lists Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) NDC 0006-3856-02 |
Merck Sharp & Dohme LLC | Not specified | To be discontinued on or near late September 2026. |
Related medications in shortage
Other Anti-Infective medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection (FDA data as of Sep 9, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/imipenem-anhydrous-cilastatin-and-relebactam-680eea.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).